Editorial Board
Reshef Tal
Yale University School of Medicine · United States
Editorial leadership for Journal of Fertility Biomarkers ISSN 2576-2818
Research interests
- Polycystic Ovarian Syndrome
- Angiogenesis
- Ovarian Reserve
- Antimullerian Hormone
- Pre-Eclampsia
Biography
- Reshef Tal graduated from the combined MD/PhD program of the Sackler School of Medicine at Tel-Aviv University in 2009, where he completed his PhD in molecular biology which focused upon angiogenic gene therapy.
- He was a post-doctoral research fellow at the University of Toronto, focusing on molecular aspects of pre-eclampsia pathogenesis.
- He completed his residency in obstetrics and gynecology at the Maimonides Medical Center, New York.
- He is currently a clinical fellow in reproductive endocrinology and infertility at Yale University School of Medicine.
- His current research interests include ovarian reserve and the roles of angiogenic factors in the pathogenesis of polycystic ovarian syndrome and its associated ovarian hyperstimulation syndrome.
Selected publications
- Ovarian reserve testing: a user’s guide 2017 cited 410×
- SARS–CoV-2 infection of the placenta 2020 cited 383×
- Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis 2015 cited 164×
- The role of AMH in the pathophysiology of polycystic ovarian syndrome 2016 cited 120×
- Potential Mechanisms for Racial and Ethnic Differences in Antimüllerian Hormone and Ovarian Reserve 2013 cited 66×
- Antimüllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012–2013 2018 cited 63×
Ranked by citation impact (Crossref) where available, newest otherwise · verified via ORCID.
Considering JFB for your work?
This journal is guided by Reshef Tal (Yale University School of Medicine) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.